iVexSol, a Boston, MA-based viral vector manufacturing company, raised $2.0m in new convertible debt funding.
The round was led by Casdin Capital and BioLife Solutions (NASDAQ:BLFS).
The company intends to use the funds to advance the development of its solutions.
Led by CEO Dr. Rodney Rietze, iVexSol is a viral vector manufacturing company founded on a proprietary, stable lentiviral vector production process that transforms the way essential gene-delivery vehicles are made. Its technology aims to reduce the complexity, cost and development time of critical reagents, thereby accelerating the development and enabling access to cell and gene therapies for CGT researchers and manufacturers.